CN Patent

CN1741803A — N－脱甲基氯氮平在治疗人神经精神疾病中的用途

Assigned to Acadia Pharmaceuticals Inc · Expires 2006-03-01 · 20y expired

What this patent protects

本发明公开了治疗包括精神病、情感病症、痴呆症、神经性疼痛及青光眼的神经精神疾病的方法。通过给予患有神经精神疾病的患者治疗有效剂量的N－脱甲基氯氮平来实施治疗。

USPTO Abstract

本发明公开了治疗包括精神病、情感病症、痴呆症、神经性疼痛及青光眼的神经精神疾病的方法。通过给予患有神经精神疾病的患者治疗有效剂量的N－脱甲基氯氮平来实施治疗。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN1741803A
Jurisdiction: CN
Classification: —
Expires: 2006-03-01
Drug substance claim: No
Drug product claim: No
Assignee: Acadia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.